Inventor
KAHVEJIAN AVAK
US32 patents
⚠️ This page may combine multiple inventors who share the name “KAHVEJIAN AVAK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
RUBIUS THERAPEUTICS INC
14 patentsUS9644180B2May 9, 2017
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC98 citations98
US10344263B2Jul 9, 2019
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC14 citations94
US10329531B2Jun 25, 2019
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC18 citations94
US10253296B2Apr 9, 2019
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC16 citations94
US10301594B1May 28, 2019
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC11 citations92
US10869898B2Dec 22, 2020
Methods and compositions for immunomodulation
RUBIUS THERAPEUTICS INC6 citations84
US10557119B2Feb 11, 2020
Erythroid cells comprising phenylalanine ammonia lyase
RUBIUS THERAPEUTICS INC4 citations84
US10301593B2May 28, 2019
Synthetic membrane-receiver complexes
RUBIUS THERAPEUTICS INC8 citations84
US10517897B1Dec 31, 2019
Methods related to engineered erythoid cells comprising 4-1BBL
RUBIUS THERAPEUTICS INC4 citations81
US10456421B2Oct 29, 2019
Compositions and methods related to engineered erythoid cells comprising 4-1BBL
RUBIUS THERAPEUTICS INC10 citations81
US10568910B2Feb 25, 2020
Compositions and methods related to engineered erythroid cells comprising IL-15
RUBIUS THERAPEUTICS INC3 citations70
US11576934B2Feb 14, 2023
Methods and compositions for immunomodulation
RUBIUS THERAPEUTICS INC0 citations62
US11554141B2Jan 17, 2023
Methods and compositions for immunomodulation
RUBIUS THERAPEUTICS INC0 citations62
US10716811B2Jul 21, 2020
Compositions and methods related to multimodal therapeutic cancer indications
RUBIUS THERAPEUTICS INC0 citations49
FLAGSHIP PIONEERING INNOVATIONS VI LLC
9 patentsUS11458156B2Oct 4, 2022
Compositions comprising circular polyribonucleotides and uses thereof
FLAGSHIP PIONEERING INNOVATIONS VI LLC10 citations92
US11160822B2Nov 2, 2021
Compositions comprising circular polyribonucleotides and uses thereof
FLAGSHIP PIONEERING INNOVATIONS VI LLC10 citations92
US11058706B2Jul 13, 2021
Compositions comprising circular polyribonucleotides and uses thereof
FLAGSHIP PIONEERING INNOVATIONS VI LLC17 citations92
US10953033B2Mar 23, 2021
Compositions comprising circular polyribonucleotides and uses thereof
FLAGSHIP PIONEERING INNOVATIONS VI LLC19 citations92
US12357653B2Jul 15, 2025
Compositions comprising circular polyribonucleotides and uses thereof
FLAGSHIP PIONEERING INNOVATIONS VI LLC1 citations73
US11844759B2Dec 19, 2023
Compositions comprising circular polyribonucleotides and uses thereof
FLAGSHIP PIONEERING INNOVATIONS VI LLC2 citations71
US12539309B2Feb 3, 2026
Compositions comprising circular polyribonucleotides and uses thereof
FLAGSHIP PIONEERING INNOVATIONS VI LLC0 citations61
US12480117B2Nov 25, 2025
Compositions comprising modified circular polyribonucleotides and uses thereof
FLAGSHIP PIONEERING INNOVATIONS VI LLC0 citations61
US12282499B1Apr 22, 2025
Database processing system for determining whether an entity affects a transition
FLAGSHIP PIONEERING INNOVATIONS VI LLC0 citations41
FLAGSHIP PIONEERING INNOVATIONS V INC
9 patentsUS10683352B1Jun 16, 2020
Methods for treating cancer using GRM8 inhibitors
FLAGSHIP PIONEERING INNOVATIONS V INC20 citations91
US11446344B1Sep 20, 2022
Anellovirus compositions and methods of use
FLAGSHIP PIONEERING INNOVATIONS V INC21 citations89
US11034751B1Jun 15, 2021
Methods and compositions for treating cancer using serotonin receptor inhibitors
FLAGSHIP PIONEERING INNOVATIONS V INC17 citations82
US11166996B2Nov 9, 2021
Anellovirus compositions and methods of use
FLAGSHIP PIONEERING INNOVATIONS V INC12 citations80
US11208475B1Dec 28, 2021
Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
FLAGSHIP PIONEERING INNOVATIONS V INC3 citations70
US10457740B1Oct 29, 2019
Methods and compositions for treating cancer using P2RX2 inhibitors
FLAGSHIP PIONEERING INNOVATIONS V INC6 citations68
US11059886B1Jul 13, 2021
Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators
FLAGSHIP PIONEERING INNOVATIONS V INC1 citations60
US11274158B2Mar 15, 2022
Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
FLAGSHIP PIONEERING INNOVATIONS V INC0 citations59
US11013717B1May 25, 2021
Methods and compositions for treating cancer using SERCA pump inhibitors
FLAGSHIP PIONEERING INNOVATIONS V INC1 citations57